GEPHARDT GROUP GOVERNMENT AFFAIRS for HEALIANCE PHARMACEUTICALS
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 20, 2012 | $50,000 | Replaced |
| 2nd Quarter - Termination Amendment (this page) | Jul 18, 2014 | $50,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
innovative diabetes treatment
Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JANICE O'CONNELL | — |
Foreign Relations FOR
innovative diabetes treatment
Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JANICE O'CONNELL | — |
Pharmacy PHA
Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.
Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JANICE O'CONNELL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.